T cells attack neurons in MS

barbara

Pioneer Founding member
The Scientist.com

Posted by Megan Scudellari
23rd September 2010

In a rare glimpse inside a diseased brain, researchers watch for the first time as immune cells directly attack neurons in a mouse model of multiple sclerosis (MS).

Published this week in Immunity, the surprising role of T helper cells in neurodegeneration may provide a novel therapeutic target for blocking neuron dysfunction in patients with MS.

"It's a beautiful paper," said Howard Gendelman, chair of the department of pharmacology and experimental neuroscience at the University of Nebraska Medical Center, who was not involved in the research. "Axonal degeneration is a big part of MS, but nobody knew until this paper what the mechanism was."

MS was first described as a demyelinating disease in which immune cells in the brain attack the protective myelin sheath around axons, tearing it apart and slowing or stopping nerve signals, leading to muscle spasms, weakness, and other symptoms of MS. Over the last decade, however, scientists have come to realize that axons are also part of the pathology of MS: Direct damage to neurons and their processes, and not just the myelin sheath, causes disability.

Frauke Zipp and colleagues at the Johannes Gutenberg University Mainz in Germany used live imaging to demonstrate how T cells cause severe, yet partially reversible, damage to axons and neuronal bodies in a mouse model of MS, mice induced with experimental autoimmune encephalomyelitis (EAE). In these mice, the team labeled neurons with green fluorescent protein and T cells with red. Then, using two-photon laser scanning microscopy, a relatively new tool that allows live imaging over several hours, the researchers observed, in real time, how T cells enter and move about the central nervous system.

The results showed that some T cells directly kiss neuronal cell bodies, forming immune-neuronal synapses, indicating communication between the two cells. The cells forming these synapses were T helper cells called Th17 cells, which have previously been implicated in MS inflammation. Indeed, time-lapse imaging showed axons falling apart at locations where synapses formed between the Th17 cells and neurons. Further experiments revealed that the Th17 cells caused an increase in calcium inside the neurons, followed by cell injury and death.

A 2001 in vitro study found that CD8 T cells, which predominate in human MS lesions, can also directly attack neurons, suggesting this may also be an important mechanism of neurodegeneration in human MS.

That's not to say that T cell-induced neuronal damage is the only cause of MS, said Zipp, as demyelinaton is obviously a significant part of the disease. "It's really not clear when and to which extent the different types of pathology take place," she said. "But what is clear is an inflammatory attack against neurons and axons is a major part [of MS] and can be reversed."

After the team determined the cause of damage, they successfully prevented it by blocking NMDA receptors, which allow calcium into a cell. When the receptors were blocked during T cell-neuron contact, calcium levels decreased.

MS symptoms do not always get worse over time, but can often get better, even without treatment, implying that there are compensatory mechanisms in the brain to regenerate areas of damage. "This was always interpreted as remyelination," said Zipp, because the myelin sheath was believed to be the main source of damage. "Now we see that these calcium changes in the neuron, induced by the T cells, can be reversed." The next step, she added, is to find neuroprotective drugs that interfere with this newly discovered mechanism of neurodegeneration.

The research also suggests a link between MS, classified as an autoimmune disease, and neurodegenerative disorders like Parkinson's disease, which are not typically linked to the immune system, said Gendelman. In a Journal of Immunology paper published earlier this year, Gendelman and colleagues found that Th17 cells are also involved in Parkinson's disease, perhaps as an immune system reaction to the buildup of toxic proteins in the brain.

"We're finding that we may want to reexamine this whole deal," said Gendelman. "It's not just multiple sclerosis that is engaging these parts of the adaptive immune system; we're seeing it in animal models reflective of Parkinson's and Alzheimer's and possibly for ALS and Huntington's disease...[The immune system] may play a part in a broader spectrum of neurological diseases."

V. Siffrin, et al., "In vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis," Immunity, 32(4):424-36, 2010.
 

Kaye

New member
Neutralization of IL-9 Ameliorates Experimental Autoimmune Encephalomyelitis by Decre

Barbara,
I read your article on MS with interest. I have also been reading about Th17 cells in severe asthma. I thought you might find this article about Th17 and IL-9 interesting. It is from this month's issure on Journal of Immunology. Medimmune is working on an anti-IL-9 mAb for severe asthma. I think it is past phase IIa but haven't read much on it, seems to be stalled. Some other articles seem to think that it can be used in other autoimmune diseases. Looks like we are moving forward on finding the culprit on autoimmune disease in general. I sure hope so.


http://www.jimmunol.org/cgi/content/abstract/jimmunol.1000986v1

Published online August 30, 2010
The Journal of Immunology, 2010, doi:10.4049/jimmunol.1000986
Copyright ? 2010 by The American Association of Immunologists, Inc.
This Article


Neutralization of IL-9 Ameliorates Experimental Autoimmune Encephalomyelitis by Decreasing the Effector T Cell Population
Hongmei Li, Bardia Nourbakhsh, Bogoljub Ciric, Guang-Xian Zhang, and Abdolmohamad Rostami
Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107

Multiple sclerosis is a CD4+ T cell-mediated autoimmune disease affecting the CNS. Multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), have been thought to be Th1-mediated diseases. However, recent studies provide strong evidence that the major pathogenic T cell subsets in EAE are Th17 cells. IL-9, a hematopoietic growth factor, is considered to be a mediator of Th17 cells, but the precise mechanisms of its action are largely unknown. The present study was designed to investigate the role of IL-9 in autoimmune demyelination. IL-9 blockade with anti?IL-9 mAb inhibited the development of EAE, reduced the serum levels of IL-17, the CNS mRNA expression of IL-17, IL-6, IFN-, and TNF-, and the myelin oligodendrocyte glycoprotein (MOG)-induced IL-17, IFN- secretion of lymphocytes. Furthermore, anti?IL-9 mAb in culture suppressed IL-17 production of MOG-reactive T cells and their potency in adoptive transfer EAE. These findings indicate that the protective effect of IL-9 blockade in EAE was likely mediated via inhibition of the development of MOG peptide-specific T cells, which in turn led to reduced infiltration of T cells into the CNS. Thus, anti?IL-9 mAb treatment may provide an effective therapeutic strategy against autoimmune diseases.

Address correspondence and reprint requests to Dr. Abdolmohamad Rostami, Department of Neurology, Thomas Jefferson University, Jefferson Hospital for Neuroscience Building, 900 Walnut Street, Philadelphia, PA 19107. E-mail address: a.m.rostami@jefferson.edu

This work was supported in part by grants from the National Institutes of Health, the National Multiple Sclerosis Society, and the Commonwealth of Pennsylvania Department of Health (to A.R.).
 

Kaye

New member
Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the develop

http://www.jci.org/120/9

Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice

Partha S. Biswas, Sanjay Gupta, Emily Chang, Li Song, Roslynn A. Stirzaker, James K. Liao, Govind Bhagat, Alessandra B. Pernis


D eregulated production of IL-17 and IL-21 plays a key pathogenic role in many autoimmune disorders. A delineation of the mechanisms that underlie the inappropriate synthesis of IL-17 and IL-21 in autoimmune diseases can thus provide important insights into potential therapies for these disorders. Here we have shown that the serine-threonine kinase Rho-associated, coiled-coil?containing protein kinase 2 (ROCK2) becomes activated in mouse T cells under Th17 skewing conditions and phosphorylates interferon regulatory factor 4 (IRF4), a transcription factor that is absolutely required for the production of IL-17 and IL-21. We furthermore demonstrated that ROCK2-mediated phosphorylation of IRF4 regulated the synthesis of IL-17 and IL-21 and the differentiation of Th17 cells. Whereas CD4+ T cells from WT mice activated ROCK2 physiologically under Th17 conditions, CD4+ T cells from 2 different mouse models of spontaneous autoimmunity aberrantly activated ROCK2 under neutral conditions. Moreover, administration of ROCK inhibitors ameliorated the deregulated production of IL-17 and IL-21 and the inflammatory and autoantibody responses observed in these autoimmune mice. Our findings thus uncover a crucial link among ROCK2, IRF4, and the production of IL-17 and IL-21 and support the idea that selective inhibition of ROCK2 could represent an important therapeutic regimen for the treatment of autoimmune disorders
 

Kaye

New member
Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation

Looks like they have figured it out. Now how do we get to use our cells in the USA?

http://www.jimmunol.org/cgi/content/abstract/185/1/302

Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype
Soufiane Ghannam,* J?r?me P?ne,* Gabriel Torcy-Moquet, Christian Jorgensen,* and Hans Yssel*
*Institut National de la Sant? et de la Recherche M?dicale, Unit? 844, H?pital St. Eloi, Universit? Montpellier I; and Institut de G?n?tique Mol?culaire de Montpellier, Centre National de la Recherche Scientifique, Montpellier, France

Mesenchymal stem cells (MSCs) exert immunomodulatory properties via the inhibition of T cell activation and proliferation. Because of the deleterious role of Th17 cells in the pathogenesis of inflammatory disease, we investigated whether proinflammatory cytokines could modify the expression of adhesion molecules on human MSCs, thereby contributing to increased Th17 cell adhesion to MSCs and, as a consequence, modulating the function of the latter cells. IFN- and TNF- synergistically enhanced the expression of CD54 by MSCs, enabling the CCR6 chemokine ligand CCL20 to induce in vitro adhesion of Th17 cells to MSCs. MSCs prevented the in vitro differentiation of naive CD4+ T cells into Th17 cells and inhibited the production of IL-17, IL-22, IFN-, and TNF- by fully differentiated Th17 cells; this was mediated, in part, via PGE2, the production of which was enhanced in cocultures with Th17 cells. Moreover, MSCs induced the production of IL-10 and trimethylation of histone H3K4me3 at the promoter of the FOXP3 gene locus, whereas it suppressed trimethylation of the corresponding region in the RORC gene in Th17 cells. These epigenetic changes were associated with the induction of fork head box p3 and the acquisition by Th17 cells of the capacity to inhibit in vitro proliferative responses of activated CD4+ T cells, which was enhanced when MSCs were preincubated with IFN- and TNF-. These results showed that, under inflammatory conditions, MSCs mediate the adhesion of Th17 cells via CCR6 and exert anti-inflammatory effects through the induction of a T cell regulatory phenotype in these cells.
Address correspondence and reprint requests to Dr. Hans Yssel, Institut National de la Sant? et de la Recherche M?dicale, Unit? 844, Centre Hospitalier Universitaire St. Eloi, 80 Avenue Augustin Fliche, 34091 Montpellier Cedex, France. E-mail address: hans.yssel@inserm.fr
 
Top